A Phase I Study to Evaluate the Safety and Pharmacokinetics of CNTO 148 Following Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects.

Trial Profile

A Phase I Study to Evaluate the Safety and Pharmacokinetics of CNTO 148 Following Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2013

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Centocor
  • Most Recent Events

    • 14 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top